Molecular Partners Past Earnings Performance
Past criteria checks 0/6
Molecular Partners has been growing earnings at an average annual rate of 3.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 8.8% per year.
Key information
3.7%
Earnings growth rate
10.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 8.8% |
| Return on equity | -45.1% |
| Net Margin | -1,042.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Molecular Partners makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6 | -63 | 19 | 0 |
| 30 Jun 24 | 8 | -58 | 19 | 0 |
| 31 Mar 24 | 7 | -59 | 19 | 0 |
| 31 Dec 23 | 7 | -62 | 20 | 0 |
| 30 Sep 23 | 9 | -60 | 21 | 0 |
| 30 Jun 23 | 9 | -62 | 22 | 0 |
| 31 Mar 23 | 20 | -50 | 23 | 0 |
| 31 Dec 22 | 190 | 118 | 23 | 0 |
| 30 Sep 22 | 189 | 117 | 22 | 0 |
| 30 Jun 22 | 190 | 118 | 21 | 0 |
| 31 Mar 22 | 182 | 106 | 20 | 0 |
| 31 Dec 21 | 10 | -64 | 18 | 0 |
| 30 Sep 21 | 9 | -67 | 16 | 0 |
| 30 Jun 21 | 6 | -72 | 14 | 0 |
| 31 Mar 21 | 7 | -66 | 12 | 0 |
| 31 Dec 20 | 9 | -63 | 12 | 0 |
| 30 Sep 20 | 11 | -53 | 11 | 0 |
| 30 Jun 20 | 14 | -48 | 12 | 0 |
| 31 Mar 20 | 17 | -43 | 13 | 0 |
| 31 Dec 19 | 20 | -36 | 14 | 0 |
| 30 Sep 19 | 17 | -37 | 13 | 0 |
| 30 Jun 19 | 14 | -38 | 12 | 0 |
| 31 Mar 19 | 12 | -38 | 11 | 0 |
| 31 Dec 18 | 10 | -37 | 10 | 0 |
| 30 Sep 18 | 17 | -27 | 9 | 0 |
| 30 Jun 18 | 23 | -18 | 9 | 0 |
| 31 Mar 18 | 22 | -24 | 9 | 0 |
| 31 Dec 17 | 20 | -25 | 8 | 0 |
| 30 Sep 17 | 17 | -26 | 8 | 0 |
| 30 Jun 17 | 16 | -28 | 7 | 0 |
| 31 Mar 17 | 19 | -22 | 8 | 0 |
| 31 Dec 16 | 23 | -19 | 7 | 0 |
| 30 Sep 16 | 27 | -13 | 22 | 0 |
| 30 Jun 16 | 31 | -3 | -1 | 0 |
| 31 Mar 16 | 30 | -2 | 21 | 0 |
| 31 Dec 15 | 29 | 0 | 6 | 0 |
| 30 Sep 15 | 28 | -6 | 20 | 0 |
| 30 Jun 15 | 25 | -11 | 21 | 0 |
| 31 Mar 15 | 26 | -5 | 15 | 0 |
| 31 Dec 14 | 27 | -2 | 18 | 0 |
| 31 Dec 13 | 32 | 7 | 15 | 0 |
Quality Earnings: MOLN is currently unprofitable.
Growing Profit Margin: MOLN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MOLN is unprofitable, but has reduced losses over the past 5 years at a rate of 3.7% per year.
Accelerating Growth: Unable to compare MOLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MOLN has a negative Return on Equity (-45.1%), as it is currently unprofitable.